SAGA Diagnostics is a leader in personalized cancer diagnostics and disease monitoring, specializing in molecular genetic analysis of circulating tumor DNA (ctDNA). Their mission centers on enhancing precision cancer medicine by developing and providing minimally invasive liquid biopsy testing services that allow for accurate treatment monitoring and improved patient outcomes. SAGA's proprietary tests enable the detection of actionable mutations, stratification of patient groups, and monitoring of treatment responses and disease recurrence with exceptional sensitivity. With a focus on innovation and quality, SAGA Diagnostics strives to support patients, oncologists, and drug developers in the fight against cancer.